

Claims

1. The use of 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-4-(2-phenoxyethyl)-2H-1,2,4-triazol-3(4H)-one (nefazodone) or of a pharmaceutically acceptable salt thereof for producing medicaments for the treatment of Parkinson's disease.
2. The use of 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one (trazodone) or of a pharmaceutically acceptable salt thereof and of 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-4-(2-phenoxyethyl)-2H-1,2,4-triazol-3(4H)-one (nefazodone) or of a pharmaceutically acceptable salt thereof for producing medicaments for the treatment of Parkinson's disease.
3. The use of cetirizine or of a pharmaceutically acceptable salt thereof for producing medicaments for the treatment of Parkinson's disease.
4. The use as claimed in claim 3, characterized in that the latter includes cetirizine dihydrochloride.
5. The use as claimed in claim 3 or 4, characterized in that the medicament includes a single dose of cetirizine of at least about 5 mg, preferably at least about 10 mg.
6. The use as claimed in any of claims 3, 4 or 5, characterized in that the cetirizine is in tablet form or in the form of a solution or suspension.
7. The use as claimed in claim 2, in which the composition comprising the trazodone or a pharmaceutically acceptable salt thereof is intended for intake in the evening.
8. The use as claimed in either of claims 2 or 7, in which the medicament is in tablet form, where the tablet intended for a single dose comprises between about 50 mg and about 200 mg of

one of the active substances nefazodone or trazodone or in each case a corresponding dose of both active substances.

9. The use as claimed in any of claims 2, 7 or 8 for producing medicaments for the treatment of depression in parkinsonian patients.
10. The use as claimed in any of claims 1 to 9 in patients simultaneously treated with L-dopamine.
11. The use as claimed in claim 3 or 4, characterized in that a daily dose totaling between about 100 mg and about 800 mg, where appropriate in a plurality of single doses, is administered to the patient.
12. The use as claimed in any of the preceding claims, characterized in that a daily dose of between about 300 and about 600 mg is administered to the patient.
13. The use as claimed in any of the preceding claims, characterized in that the nefazodone or its pharmaceutically acceptable salt is administered in two to three single doses.
14. The use as claimed in any of the preceding claims, characterized in that the nefazodone or its pharmaceutically acceptable salt is administered in one or more single doses each of about 100 mg to about 200 mg.
15. The use as claimed in any of the preceding claims, characterized in that the nefazodone or its pharmaceutically acceptable salt is administered in tablet form intended for oral intake.
16. The use as claimed in any of the preceding claims in conjunction with intake of a caffeine- and/or acetylsalicylic acid-containing composition in the same period for the treatment of Parkinson's disease.

17. A pharmaceutical active substance combination comprising 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-4-(2-phenoxyethyl)-2H-1,2,4-triazol-3(4H)-one (nefazodone) or a pharmaceutically acceptable salt thereof and 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-1,2,4-triazolo[3,4-a]pyridin-3(2H)-one (trazodone) as combination product for simultaneous, separate or sequential use in the therapy of Parkinson's disease.
18. The pharmaceutical active substance combination as claimed in claim 17 comprising at least one antihistamine or a pharmaceutically acceptable salt thereof besides nefazodone or trazodone as combination product for simultaneous, separate or sequential use in the therapy of Parkinson's disease.
19. The pharmaceutical active substance combination as claimed in claim 18, characterized in that the latter includes cetirizine or one of its pharmaceutically acceptable salts as antihistamine.
20. The pharmaceutical active substance combination as claimed in any of claims 17 to 19, characterized in that at least the nefazodone/trazodone is in tablet form, where a tablet intended for a single dose comprises between about 50 mg and about 200 mg of at least one of the active substances nefazodone and/or trazodone or in each case a corresponding dose of both active substances.
21. The pharmaceutical active substance combination as claimed in any of claims 18 to 20, characterized in that the antihistamine includes cetirizine or its hydrochloride.
22. The pharmaceutical active substance combination as claimed in any of claims 18 to 21, characterized in that cetirizine or one of its pharmaceutically acceptable salts is in tablet form, and a single dose comprises at least about 5 mg, preferably at least about 10 mg, of this active substance.